Search Results
Your search for ,Non matches 5542 pages
Showing 851 - 900MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Homoharringtonine-Based Induction in Pediatric AML
In a Chinese study (CCLG-AML 2015) reported in the Journal of Clinical Oncology, Li et al found that homoharringtonine (HHT)-based induction therapy was associated with promising outcomes in pediatric acute myeloid leukemia (AML). As stated by the investigators, “HHT is commonly used for the...
FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On August 11, the U.S. Food and Drug Administration (FDA) approved the fixed-dose combination of niraparib and abiraterone acetate (Akeega), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by...
FDA Approves Pralsetinib for RET Fusion–Positive NSCLC
On August 9, the U.S. Food and Drug Administration (FDA) granted regular approval to pralsetinib (Gavreto) for adults with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. ARROW Trial Pralsetinib was previously granted accelerated approval for...
CAR T-Cell Therapies: Trends and Indications
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
On the Art of Organizing Best of ASCO Meetings
Preparing and running a medical conference is usually a complex but rewarding mission. It is a demanding job that is typically done voluntarily by physicians and educators who are dedicated to professional and community service; advancement of research and education; as well as the dissemination of ...
Fine Particulate Matter Exposure May Increase Risk of Primary Cancers Other Than Lung Cancer
Chronic exposure to fine particulate air pollutants (PM2.5, particulate matter 2.5 µm in diameter) and nitrogen dioxide (NO2) may increase non-lung cancer risk in older adults, according to a study published by Yaguang et al in Environmental Epidemiology. In a cohort study of millions of Medicare...
Study Shows Substantial Racial and Ethnic Disparities Among Survivors of Second Primary Cancers in the United States
In a new study published by Hyuna Sung, PhD, and colleagues in JAMA Network Open, non-Hispanic Black individuals diagnosed with a second primary cancer experienced 21% higher cancer-related death rates and 41% higher cardiovascular-related death rates compared with non-Hispanic White individuals;...
Translating Consent Documents: Potential Barrier for Including Underrepresented Groups in Clinical Trials
Cancer research centers conducting clinical trials could potentially enroll more patients from underrepresented racial and ethnic groups by placing a greater emphasis on relieving investigators of the costs of translating consent documents into languages other than English, according to a study...
Outcomes With Cancer-Associated Isolated Distal Deep-Vein Thrombosis
In a registry-based study reported in the Journal of Clinical Oncology, Galanaud et al found that outcomes in patients with cancer-associated isolated distal deep-vein thrombosis (DVT) were similar to those in patients with cancer-associated proximal DVT. Study Details The study included data from ...
Three Studies From ASCO 2023 Focus on Metastatic Castration-Resistant Prostate Cancer
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
Wildfire Exposure and Survival Outcomes After Surgery for NSCLC
Investigators have found that exposure to wildfires within 1 year of surgery may significantly lower the chance of survival in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Zhang et al in JAMA Oncology. Background Lung cancer is the second most common...
Camrelizumab Plus Rivoceranib vs Sorafenib in Unresectable Hepatocellular Carcinoma
In a largely Asian phase III study (CARES-310) reported in The Lancet, Qin et al found that the combination of camrelizumab and rivoceranib (also known as apatinib) significantly prolonged progression-free and overall survival vs sorafenib in the first-line treatment of unresectable or metastatic...
Expert Point of View: Anand Ashwin Patel, MD
As presented at the 2023 ASCO Annual Meeting, the phase III IMerge trial of imetelstat1 and the phase III COMMANDS trial of luspatercept2 met their primary endpoints of transfusion independence. The findings suggest that lower-risk patients with transfusion-dependent, non-del(5q) myelodysplastic...
IMerge Trial: Use of Imetelstat Reduces Transfusion Dependence in Lower-Risk MDS
In the primary analysis of the phase III randomized, double-blind, placebo-controlled IMerge trial, in those achieving the primary endpoint of 8-week transfusion independence, treatment with imetelstat significantly reduced transfusion dependence—for a median duration of 1 year—and improved a...
Short Bursts of Vigorous Daily Activity May Be Linked to Reduced Cancer Incidence
Investigators have found that just 4.5 minutes of vigorous activity per day could reduce the risk of some cancer types by up to 32%. The results of the recent study were published by Stamatakis et al in JAMA Oncology. Background Vigorous intermittent lifestyle physical activity describes very...
Addition of Nivolumab to SABR in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In the phase II I-SABR trial reported in The Lancet, Chang et al found that the addition of nivolumab to stereotactic ablative radiotherapy (SABR) improved event-free survival in patients with previously untreated stage I or II or isolated parenchymal recurrent node-negative non–small cell lung...
Third-Line Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is Part 3 of Clinical Advances in Diffuse Large B-Cell Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jeremy Abramson, Laurie Sehn, and Kieron Dunleavy discuss the third-line treatment of relapsed/refractory...
Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
This is Part 1 of Clinical Advances in Diffuse Large B-Cell Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jeremy Abramson, Laurie Sehn, and Kieron Dunleavy discuss the treatment of newly diagnosed high-risk diffuse...
Stereotactic Radiosurgery Before Resection of Brain Metastases From Solid Tumors
In a study reported in JAMA Oncology, Prabhu et al identified outcomes and associated risk factors among patients receiving stereotactic radiosurgery (SRS) prior to resection of brain metastases from solid tumors. Study Details The study involved data from an international multicenter cohort...
Addition of SBRT to Immunotherapy in Advanced Solid Tumors
In the Belgian phase II CHEERS trial reported in JAMA Oncology, Spaas et al evaluated the addition of stereotactic body radiotherapy (SBRT) to anti–PD-1/PD-L1 immune checkpoint inhibitor therapy, with SBRT directed to a maximum of three lesions, in patients with advanced solid tumors. The...
First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy
In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) who were ineligible for platinum-based chemotherapy. Study Details In the open-label...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
Incorporation of Gilteritinib Into Induction and Consolidation Chemotherapy and as Maintenance Therapy in Newly Diagnosed Patients With AML
In a phase Ib trial (2215-CL-0103) reported in the Journal of Clinical Oncology, Keith W. Pratz, MD, and colleagues found that incorporation of the FLT3 inhibitor gilteritinib into intensive induction and consolidation chemotherapy and its use as single-agent maintenance therapy were associated...
Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial
As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit with osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC)....
Berberine
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the use of...
First-Line Pembrolizumab/Lenvatinib in Advanced Non–Clear Cell Renal Cell Carcinoma
In the phase II KEYNOTE-B61 trial reported in The Lancet Oncology, Laurence Albiges, MD, PhD, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal cell carcinoma. As stated by the investigators,...
Lazertinib vs Gefitinib in the First-Line Treatment of EGFR-Mutated Advanced NSCLC
In a phase III trial (LASER301) reported in the Journal of Clinical Oncology, Byoung Chul Cho, MD, PhD, and colleagues found that lazertinib improved progression-free survival vs gefitinib in the first-line treatment of EGFR-mutated advanced non–small cell lung cancer (NSCLC). As stated by the...
APOBEC3A Protein May Be Linked to Drug Resistance in Patients With NSCLC
Researchers have uncovered how non–small cell lung cancer (NSCLC) tumors may develop drug resistance over time and identified the APOBEC3A protein as a potential target for novel cancer therapeutics, according to a study published by Isozaki et al in Nature. The findings point to potential...
Use of Zipalertinib in Previously Treated Patients With Advanced NSCLC and EGFR Exon 20 Insertions
In a phase I/IIa study reported in the Journal of Clinical Oncology, Piotrowska et al found that the EGFR tyrosine kinase inhibitor zipalertinib showed activity and an acceptable safety profile in previously treated patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20...
Pembrolizumab-Based Combination Therapies May Improve Outcomes in Advanced NSCLC
Researchers have revealed that combining pembrolizumab with other treatments may reduce the size of target tumors, resulting in a higher response rate for patients with advanced non–small cell lung cancer (NSCLC), according to a recent study published by Gutierrez et al in Nature Medicine. “We are...
MLH1 Methylation Status and Screenings for Colorectal or Endometrial Cancer
New research could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, according to a novel study published by Hitchins et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings suggest that the guidelines leave a...
PHERGain: Adapted-Response Trial Guides Treatment With Dual HER2 Blockade Alone
The phase II PHERGain trial, which employed a response-adapted strategy in the treatment of early-stage, HER2-positive breast cancer, has shown promising results for the selective use of HER2 blockade and de-escalation of chemotherapy.1 Nearly all patients assigned to skip chemotherapy prior to...
Patients With Prostate Cancer May Face High Rates of Financial Toxicity
About 50% of patients with metastatic prostate cancer may experience financial hardship as a result of their treatment, according to a new study published by Joyce et al in The Journal of Urology. Background "Our most significant finding may be that patients experience financial toxicity despite...
ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Expert Point of View: Mark Awad, MD, PhD
Formal discussant of KEYNOTE-671, Mark Awad, MD, PhD, of the Dana-Farber Cancer Institute, Boston, was optimistic about these data. “A hazard ratio of 0.58 for event-free survival and signals favoring overall survival in stage II to III non–small cell lung cancer [NSCLC] are truly impressive....
KEYNOTE-671 Trial: Perioperative Pembrolizumab Plus Chemotherapy Improves Outcomes in Stage II and III NSCLC
Neoadjuvant therapy with pembrolizumab plus platinum-based chemotherapy followed by surgery and then adjuvant pembrolizumab led to significantly improved event-free survival in patients with resectable stage II and III non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy...
Expert Point of View: Benjamin J. Solomon, MBBS, PhD
“Outcomes for patients with early-stage non–small cell lung cancer [NSCLC] remain poor despite potentially curative surgery and adjuvant cisplatin-based chemotherapy,” said formal abstract discussant Benjamin J. Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre and the University of Melbourne....
Adjuvant Osimertinib Improves Overall Survival in Resectable EGFR-Mutated NSCLC
The phase III ADAURA trial previously found that adjuvant use of osimertinib improved disease-free survival for completely resected EGFR-mutated non–small cell lung cancer (NSCLC) in patients with stage IB, II, or IIIA disease.1 The final analysis of ADAURA, which was presented at the 2023 ASCO...
Intracranial Activity of Adagrasib in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
In an analysis reported in the Journal of Clinical Oncology, Negrao et al identified outcomes in the KRYSTAL-1 trial among patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC) who had untreated central nervous system (CNS) metastases at baseline and were treated with...
Medicaid Expansion May Be Linked to Increase in Palliative Care for Patients With Advanced Cancers
The expansion of Medicaid coverage under the Affordable Care Act may be associated with the largest increases in critical palliative care services for patients with advanced cancers in the United States, according to a new study published by Han et al in Health Affairs. The findings uncovered how...
Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
TROP-2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Advanced NSCLC
In a phase I study (TROPION-PanTumor01) reported in the Journal of Clinical Oncology, Shimizu et al described outcomes with the trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate datopotamab deruxtecan at the dose selected for further development in patients with advanced...
Novel Radiotracer May Accurately Detect and Differentiate Renal Cell Carcinomas
The positron-emission tomography (PET) tracer zirconium (Zr)-89–DFO-girentuximab may accurately identify patients with clear cell renal cell carcinoma and differentiate the disease from other types of renal tumors, according to findings presented by Calais et al at the Society of Nuclear Medicine...
LGBTQ+ Patients and Survivors of Cancer Expressed Concern Over Discrimination in Health-Care Settings, According to New Survey
About 50% of LGBTQ+ patients and survivors of cancer may be concerned about facing discrimination in a health-care setting, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). The new findings demonstrated that these concerns and experiences with...
FDA Approves Iopromide Injection for Contrast-Enhanced Mammography
Iopromide-300 and -370 (Ultravist), an iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography—making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of...
